Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Perspective Therapeutics ( (CATX) ).
On April 18, 2026, Perspective Therapeutics posted interim data from its ongoing Phase 1/2a trial of [212Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors, alongside an updated corporate presentation, and on April 20, 2026 it issued a press release as the data were presented at the AACR 2026 meeting in San Diego. The March 4, 2026 data cutoff showed the therapy was generally well tolerated in 64 treated patients with no dose-limiting toxicities, no grade 4 or 5 adverse events, no treatment-related discontinuations or serious renal complications, and emerging clinical activity including a 43% objective response rate in the first half of Cohort 2 and 72% of early cohort patients remaining progression-free, underscoring potential competitive positioning in advanced neuroendocrine tumor care as higher-dose cohorts continue treatment and follow-up.
The most recent analyst rating on (CATX) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Perspective Therapeutics stock, see the CATX Stock Forecast page.
Spark’s Take on CATX Stock
According to Spark, TipRanks’ AI Analyst, CATX is a Neutral.
The score is held down primarily by weak financial performance (no current revenue, widening losses, and rising cash burn). Technical indicators also point to soft momentum. These negatives are partially offset by positive pipeline/manufacturing updates and strengthened funding from recent capital raises.
To see Spark’s full report on CATX stock, click here.
More about Perspective Therapeutics
Perspective Therapeutics, Inc. operates in the radiopharmaceuticals and oncology drug development industry, focusing on targeted alpha therapies for cancer. Its lead investigational product, [212Pb]VMT-α-NET, is designed to diagnose and treat unresectable or metastatic neuroendocrine tumors that express somatostatin receptor subtype 2, addressing patients with advanced disease who often have limited options.
Average Trading Volume: 3,421,147
Technical Sentiment Signal: Hold
Current Market Cap: $499M
See more data about CATX stock on TipRanks’ Stock Analysis page.